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Abstract: With the increasing popularity of herbomineral preparations in healthcare, a new proprietary herbomineral 
formulation was formulated with ashwagandha root extract and minerals viz. zinc, magnesium, and selenium. The aim of the 
study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect
®
) on the herbomineral 
test formulation using mice splenocytes. The test formulation was divided into two parts. One part was the control without the 
Biofield Treatment. The other part was labelled the Biofield Treated sample, which received the Biofield Energy Healing 
Treatment remotely from twenty renowned Biofield Energy Healers. The splenocyte cells were exposed with the test 
formulation at ranges of 0.00001053 to 10.53 µg/mL for cell viability by MTT assay, with cell viability ranging from 77.50% 
to 176.52%. TNF-α was significantly inhibited by 15.88%, 15.28%, 12.30%, 12.60%, and 22.72% at 0.00001053, 0.001053, 
0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the vehicle control (VC). 
TNF-α was significantly reduced by 2.33% and 8.35% at 1.053 and 10.53 µg/mL, respectively compared to the untreated test 
formulation. IL-1β was significantly reduced by 30.81%, 27.36%, 23.92%, 18.40%, 11.27%, and 21.16% at 0.00001053, 
0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively in the Biofield Treated test formulation compared to the 
VC. IL-1β was significantly reduced by 48.63% (p≤0.001) and 15.28% at 0.00001053 and 0.0001053 µg/mL, respectively in 
the Biofield Treated test formulation compared to the untreated test formulation. MIP-1α expression was inhibited by the 
Biofield Treated test formulation and showed immunosuppressive activity at 0.01053, 0.1053, 1.053, and 10.53 µg/mL by 
22.33%, 16.25%, 15.58%, and 21.83%, respectively compared to the VC. The Biofield Treated test formulation significantly 
reduced the MIP-1α expression by 13.27% and 15.67% (p<0.05) at 0.01053 and 10.53 µg/mL, respectively compared to the 
untreated test formulation. The results showed the expression of IFN-γ was significantly reduced by 33.45%, 25.38%, 37.15%, 
27.74%, 32.44%, 23.03%, and 44.21% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, and 10.53 µg/mL, 
respectively in the Biofield Treated test formulation compared to the VC. Further, the IFN-γ level was significantly decreased 
by 19.02% at 10.53 µg/mL in the Biofield Treated test formulation compared to the untreated test formulation. Overall, the 
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results demonstrate that The Trivedi Effect
® 
Biofield Energy Healing (TEBEH) significantly enhanced the anti-inflammatory 
and immunomodulatory properties of the treated formulation, and may also be useful in organ transplants, anti-aging, and 
stress management by improving overall health and quality of life. 
Keywords: Biofield Energy Healing Treatment, Biofield Energy Healers, The Trivedi Effect®, Inflammation, 
Immunomodulation, Splenocytes, MIP-1α, IL-1β, TNF-α, IFN-γ 
 
1. Introduction 
Herbomineral formulations have always been a major 
target for scientific research due to their significant 
immunomodulatory potential. Plant products and their 
extracts are used in both allopathic health care as well as 
complementary and alternative health care in order to 
improve overall health and the immune system [1, 2]. 
However, much attention has been focused on discovering 
herbal products with immunomodulatory activity along with 
low toxicity and better bioavailability [3]. Many scientific 
studies have identified the immunomodulatory properties of 
medicinal plants, which can be further potentiated with the 
addition of some minerals that regulate the immune cells. 
These types of formulations are commonly defined as 
herbomineral formulations and are the major target for 
pharmaceutical companies as phytopharmaceutical products 
or as dietary supplements. Based on the literature, a new 
proprietary herbomineral formulation was formulated with a 
combination of the herbal root extract ashwagandha 
(Withania somnifera) and three minerals viz. zinc, 
magnesium, and selenium. All the ingredients of the 
formulation in this present study possess important activities 
such as immune-modulatory, anti-inflammatory, antioxidant, 
anti-infective, and anti-viral properties [4-7]. Ashwagandha 
has been reported to have an effect on biological activity 
mainly due to the presence of withanolides, and it is used as 
an herbal medicine in alternative and complementary 
therapies [8, 9]. Apart from its common attributes such as 
antibacterial, immunomodulatory and antitumor effects, 
many clinical and preclinical data have been available with 
respect to its immunomodulatory impact [4, 10]. Minerals 
such as selenium, zinc, and magnesium have been shown to 
have significant importance in modulating the immune 
system, and their synergistic impact has been well-defined 
[5]. Scientific research has documented that in the presence 
of minerals, herbal medicines have been found to exhibit a 
high level of phagocytic index and improved antibody titer 
[11]. These formulations can be used for better therapeutic 
effects in immune compromised patients affected with 
cardiovascular diseases, age and stress related diseases, 
cancer, and autoimmune disorders. Along with herbomineral 
formulations, the Biofield Energy Healers in this study have 
used energy medicine (Biofield Energy Healing Treatments) 
as a complementary and alternative approach to study the 
impact of Biofield Energy Treatments on the specified 
herbomineral formulation for its immunomodulatory 
potential with respect to the pro-inflammatory cytokines in 
splenocyte cells isolated from mice.  
According to scientific studies and clinical trials, Biofield 
Energy Treatments have been reported to have significant 
outcome in terms of the enhanced immune function of 
cervical cancer patients with therapeutic touch [12] and 
massage therapy [13], etc. The National Center of 
Complementary and Integrative Health (NCCIH) has 
recognized and accepted Biofield Energy Healing as a 
Complementary and Alternative Medicine (CAM) health care 
approach in addition to other therapies, medicines and 
practices such as yoga, deep breathing, meditation, natural 
products, Qi Gong, mindfulness, massage, traditional 
Chinese herbs and medicines, Ayurvedic medicine, 
chiropractic/osteopathic manipulation, acupuncture, Tai Chi, 
acupressure, healing touch, special diets, naturopathy, 
progressive relaxation, homeopathy, guided imagery, 
relaxation techniques, hypnotherapy, movement therapy, 
pilates, essential oils, aromatherapy, cranial sacral therapy, 
rolfing structural integration, applied prayer (as is common in 
all religions, like Buddhism, Hinduism, Christianity and 
Judaism), and Reiki. To this day, Biofield Energy Healing 
has had significant impact in the transformation of living 
organisms and nonliving materials including metals, 
ceramics, polymers, chemicals, and pharmaceutical 
compounds. Human Biofield Energy has subtle energy that 
has the capacity to work in an effective manner [14]. Reports 
show that Complementary and Alternative Medicine (CAM) 
therapies have been practiced worldwide with clinical 
benefits in different health disease profiles [15]. This energy 
can be harnessed and transmitted by individuals into living 
organisms and non-living things via the process of Biofield 
Energy Healing. Biofield Energy Treatments (The Trivedi 
Effect
®
) have been extensively studied with significant 
outcomes in many scientific fields such as cancer science 
[16, 17], altering microbial characteristics and features 
including changing the microbial sensitivity of pathogenic 
microbes in microbiology [18-21], genetics [22, 23], altered 
physical and chemical compounds in pharmaceutics [24-27], 
improved the overall productivity, quality and yield of crops 
and plants in agricultural science [28-31], and in materials 
science where The Trivedi Effect
®
 has demonstrated its 
ability to alter the structural, thermal and physical properties 
of metals, polymers, chemicals and ceramics [32-35]. The 
authors of this study sought to evaluate the impact of Biofield 
Energy Treatment (The Trivedi Effect
®
) on the given 
herbomineral formulation, which might improve its 
immunomodulatory function in an in vitro cellular model 
with mice splenocyte cells. 
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2. Materials and Methods 
2.1. Chemicals and Reagent 
Lipopolysaccharide (LPS), 3-(4, 5-diamethyl-2-thiazolyl) 
2, 5 diphenyl-2 H-tetrazolium) (MTT), Roswell Park 
Memorial Institute (RPMI-1640), L-glutamine, penicillin, 
streptomycin, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 2- mercaptoethanol, concanavalin A (Con-A), 
rapamycin, NaHCO3, and EDTA were purchased from Sigma 
Chemical Corp. (St. Louis, MO), a subsidiary of Sigma-
Aldrich Corporation. ELISA (enzyme-link immunosorbent 
assay) assay kits for all cytokines tumor necrosis factor alpha 
(TNF-α), macrophage inflammatory protein-1α (MIP-1α), 
and interleukin-1 beta (IL-1β) were purchased from R&D 
Systems, USA. Fetal bovine serum (FBS) was purchased 
from GIBCO, USA. Ashwagandha (Withania somnifera) root 
extract powder (≥ 5% of total withanolides) was procured 
from Sanat Products Ltd., India. Zinc chloride and 
magnesium (II) gluconate hydrate were procured from Tokyo 
Chemical Industry Co., Ltd. (TCI), Japan. Sodium selenate 
was procured from Alfa Aesar, USA. All other chemicals 
used were of analytical grade available in India. 
2.2. Test Formulation and Reference Standard 
The test formulation contained four ingredients: 
ashwagandha root powder extract, zinc chloride, sodium 
selenite, and magnesium gluconate. LPS was used as an 
inflammatory stimulant, while Con-A and rapamycin were 
used as reference standards (the positive control) for 
immunostimulatory and immunosuppressive action, 
respectively in splenocytes assay.  
2.3. Experimental Animal 
C57BL/6 male mice (8 weeks old, 22 gm body weight) 
were purchased from Vivo Bio Tech Ltd., Hyderabad, India 
and acclimatized for one week prior to the experiments. The 
mice were maintained under controlled conditions with a 
temperature of 22 ± 3°C, humidity of 30% to 70% and a 12-
hour light/12-hour dark cycle and laboratory rodent diet and 
drinking tap water were provided ad libitum. All the 
procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH). The approval of the 
Institutional Animal Ethics Committee (IAEC) was obtained 
prior to carrying out the animal experiment. 
2.4. Biofield Energy Healing Strategies 
The herbomineral formulation was divided into two parts. 
One part of the test formulation did not receive any sort of 
treatment and was defined as the control group, while the 
Biofield Energy Treatment was given to the other part of the 
herbomineral formulation, which was defined as the treated 
formulation group. The Biofield Energy Treatment was 
provided by a group of twenty Biofield Energy (The Trivedi 
Effect
®
) Healers, thirteen of which were remotely located in 
the U. S. A., five in Canada, and two in Australia. The test 
formulation was located in Dabur Research Foundation near 
New Delhi in Ghaziabad, India. This Biofield Energy 
Treatment was administered for 5 minutes through the 
Healers’ unique Energy Transmission process remotely to the 
test formulation, which was kept under standard laboratory 
conditions. None of the Biofield Energy Healers in this study 
visited the laboratory in person, nor had any contact with the 
herbomineral samples. Similarly, the control sample was kept 
under the same laboratory conditions and was subjected to 
“sham” healers for five minutes. The sham healers did not 
have any knowledge about the Biofield Energy Treatment. 
After that, the Biofield Energy treated and untreated test 
formulations were kept in similar sealed conditions and used 
for the in vitro study on splenocyte cells for cytokines 
estimation. 
2.5. Experimental Design 
The experimental study was divided into 7 groups. Group 1 
comprised of the splenocyte cells without LPS and was 
denoted as the negative control. Group 2 served as a stimulant 
group that included cells with LPS. Group 3 included the 
splenocyte cells with LPS along with the vehicle (0.005% 
DMSO) and was denoted as the vehicle control. Groups 4 and 
5 were defined as the positive control, which included cells 
with Con-A (0.5 µg/mL) and rapamycin (1 nM and 10 nM), 
respectively. Groups 6 and 7 were denoted as the test item 
groups that included splenocyte cells with LPS along with the 
untreated and Biofield Treated test formulations, respectively, 
at concentrations 0.00001053 to 10.53 µg/mL. After 48 hours 
of incubation, supernatants were analyzed for the secreted 
levels of TNF-α, MIP-1α, and IL-1β using ELISA as per the 
manufacturer’s instructions. Concentrations were determined 
in triplicate wells of each sample. 
2.6. Isolation of Mouse Splenocytes 
C57BL/6 male mice were sacrificed and their spleens were 
aseptically removed and grounded by passing them through a 
sterile plastic strainer under aseptic conditions. After the cells 
were centrifuged twice at 1000 g for 5 minutes, erythrocytes 
were lysed by a lysis buffer (0.15 M NH4Cl, 0.01 M 
NaHCO3, and 0.1 mM EDTA, pH 7.4) and then the cell 
pellets were washed twice with the RPMI-1640 medium. 
Further, the cells were resuspended in the complete RPMI-
1640 medium (RPMI 1640 medium plus 10% fetal bovine 
serum, 2 mM glutamine, 100 IU/mL of penicillin and 
streptomycin, 15 mM HEPES and 50 mM 2-
mercaptoethanol). The cell counts were performed using a 
hemocytometer and cell viability was determined using the 
trypan-blue dye exclusion technique with the results showing 
≥95% of viable cells. The cells were cultured in 96-well 
tissue culture plates with 0.2 x 10
6
 cells per well. They were 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 
the indicated period [36].  
2.7. Cell Culture and Test Formulation Treatment 
Splenocyte (0.2 x 10
6
 cells per well) cells were grown in 
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96-well culture plates using a RPMI-1640 medium 
supplemented with 10% FBS, 100 units/mL of penicillin, and 
100 µg/mL of streptomycin. LPS (50 ng/mL) induced 
splenocyte cells cultures were grown for 48 hours at 37
o
C in 
a humidified CO2 incubator (5% CO2). The effect of 
cytotoxicity from the formulation was tested by treating cells 
with different concentrations of the test formulation in 
RPMI-1640 medium. Various concentrations of the test 
formulation were used i.e. 0.00001053 µg/mL to 10.53 
µg/mL in the presence of inflammatory stimulus (LPS) for 
cell viability assay. The respective vehicle controls (DMSO) 
were kept in the assay for comparison. 
2.8. Cytotoxicity by MTT Assay 
The effects of the Biofield Treated and untreated test 
formulations on cell viability at the concentration range of 
0.00001053 µg/mL to 10.53 µg/mL was tested using 3- (4, 5-
dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
(MTT) assay. The number of viable cells was determined by 
the ability of mitochondria to convert MTT to formazan dye. 
Splenocyte cells were cultured overnight in 96-well plates, at 
a density of 0.2 x 10
6
 cells per well. After treatment with the 
test formulation and incubation period, the medium was 
removed. 20 µL of 5 mg/mL MTT was then added to each 
well and incubated for 3 hours further at 37°C in a 
humidified 5% CO2 atmosphere. The cells were centrifuged 
and supernatants were removed. The cell pellets in each well 
were resuspended in 150 µL of DMSO to dissolve formazan 
crystals. The optical density of each well was read at 540 nm 
using a BioTek Reader (SIAFRT/Synergy HT multimode 
reader, US).  
The effect of the test formulation on the cell viability of 
splenocyte cells was determined with equation (1):  
%	Cell	viability = 100 −%	cytotoxicity              (1) 
Where; % cytotoxicity = [(O. D. of control cells – O. D. of 
cells treated with the test formulation)/O. D. of control 
cells]*100.  
The concentrations that resulted in >75% viability were 
selected for subsequent cytokine estimation.  
2.9. Determination of Cytokines (TNF-α, IFN-γ, and IL-1β) 
and Chemokine (MIP-1α) Using ELISA 
The in vitro activity of the Biofield Treated and untreated 
test formulations were estimated on the mice splenocyte cells 
for the production of TNF-α, IFN-γ, MIP-1α, and IL-1β using 
enzyme-linked immunosorbent assay (ELISA). The ELISA 
plates were coated with an antibody in a coating buffer at the 
recommended concentration and kept overnight at 4°C. After 
washing with PBS-T (PBS with 0.05% Tween 20), the plates 
were blocked with assay diluent for at least 2 hours at room 
temperature. A total of 100 µL culture supernatant from 
different experimental samples and standards were incubated 
overnight at 4°C and, after three washes, biotinylated anti-
mice cytokine (TNF-α, IFN-γ, MIP-1α, and IL-1β) antibodies 
at the recommended concentrations were incubated for 1 
hour at room temperature and the plates were incubated for 
45 minutes at room temperature with gentle shaking. The 
plates were again washed 3 times and then 100 µL of 
horseradish per-oxidase (HRP)–streptavidin conjugate 
solution was added and the plate was incubated for 45 
minutes at room temperature with gentle shaking. Next, the 
plate wells were washed 3 times as previously done and 100 
µL of 3,3,5,5'-tetramethylbenzidine (TMB) one-step substrate 
reagent was added, followed by a 30-minute incubation at 
room temperature in the dark. Further, 50 µL of 0.2 mole/L 
sulphuric acid was added to each well to stop the reaction 
and the plates were read for absorbance at 450 nm using a 
BioTek Reader (SIAFRT/Synergy HT multimode reader). 
Standards were run in parallel to the samples, and the 
concentrations were determined in triplicates for each sample 
[37]. 
2.10. Statistical Analysis 
Data were expressed as mean ± standard error of mean 
(SEM) and subjected to one-way analysis of variance 
(ANOVA) followed by Dunnett’s test for multiple 
comparison and Student’s t-test for two groups comparison. 
Statistical significance was considered at p≤0.05. 
3. Results 
3.1. In vitro Splenocyte Cells Viability by MTT Assay 
In vitro splenocyte cells viability was performed after 48 
hours using MTT assay, and the results are presented in 
Figure 1 with respect to the positive control, vehicle control, 
and the test formulation at different tested concentrations. 
The results showed a significant change in the percentage of 
cell viability in the tested concentrations of the test 
formulation after receiving the Biofield Energy Treatment. 
Con-A and rapamycin showed immunostimulatory and 
immunosuppressive action, respectively, and were used as 
the positive control in the experiment. The untreated cells, 
LPS, and Con-A group showed 100%, 187.74%, and 94.87% 
cell viability, respectively. The vehicle control group reported 
with 100% and the rapamycin group as 136.85%, 132.28%, 
136.52%, and 120.54% at concentrations 0.01, 0.1, 1, and 10 
nM, respectively. With respect to the vehicle control, the 
percentage of cell viability was increased, which might be 
due to proliferation in the cell culture. The tested 
concentration range from 0.00001053 to 10.53 µg/mL of the 
herbomineral test formulation was selected for the splenocyte 
cells. The test formulation was found safe at all the tested 
concentrations, with percentage viability ranging from 
77.50% to 176.52%. The % cell viability of LPS alone at 0.5 
µg/mL was significantly increased by 87.74%, while con-A 
decreased the cell viability at the same concentration as 
compared to the untreated cells. The percentage of cell 
viability was significantly increased by 10.09%, 8.90%, and 
10.30% at the concentrations 0.0001053, 0.001053, and 
0.01053 µg/mL, respectively in the Biofield Energy Treated 
test formulation as compared to the vehicle control (Figure 1).  
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Figure 1. MTT assay in splenocyte cells after 48 hours of treatment with various concentrations of the test formulation in the presence of 0.5 µg/mL of LPS. 
The absorbance of the MTT formazan was determined at 540 nm in an ELISA reader. Cell viability was denoted as the absorbance ratio (expressed as a 
percentage) of the test formulation treated cells relative to the untreated vehicle cells. Values are represented as mean ± SEM. RAP: Rapamycin; LPS: 
Lipopolysaccharide; Con-A: Concanavalin-A. 
3.2. Estimation of TNF-α Expression 
An estimation of TNF-α expression in splenocyte cells 
after treatment with the test formulation is represented in 
Figure 2. The level of TNF-α was 232.05%, 211.54%, 
262.50%, and 229.81% in the positive control group 
(rapamycin) at 0.01, 0.1, 1, and 10 µg/mL, respectively. The 
expression of TNF-α was significantly reduced by 34.13%, 
32.34%, 20.83%, 17.76%, 30.46%, 10.52%, and 15.68% at 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, 
and 10.53 µg/mL, respectively in the untreated test 
formulation as compared to the VC. The Biofield Energy 
Treated test formulation showed a significant reduction of 
TNF-α expression by 15.87%, 8.04%, 15.28%, 4.56%, 
12.30%, 12.60%, and 22.72% at the concentrations 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, 
and 10.53 µg/mL, respectively as compared to the vehicle 
control (VC). Further, the Biofield Energy Treated test 
formulation showed significant inhibition of TNF-α at 1.053 
and 10.53 µg/mL by 2.33% and 8.35%, respectively as 
compared to the untreated test formulation. The expression of 
TNF-α in the rest of the concentrations were also altered 
(Figure 2). 
 
Figure 2. The effect of the test formulation on TNF-α secretion in LPS mediated splenocyte cells was measured after 48 hours of treatment. The values are 
represented as mean ± SEM. RAP: Rapamycin; LPS: Lipopolysaccharide; Con-A: Concanavalin-A. 
3.3. Estimation of IL-1β Expression 
The expression of IL-1β in mouse splenocytes in the 
presence of the test formulation is demonstrated in Figure 3. 
The positive control rapamycin showed up to 35.85 ± 2.85 
pg/mL of IL-1β. The untreated test formulation showed 
significant reduction of IL-1β expression by 14.26%, 
24.61%, 19.78%, 18.17%, 15.87%, and 22.31% at 
0.0001053, 0.001053, 0.01053, 0.1053, 1.053 and 10.53 
µg/mL, respectively as compared to the VC group. Moreover, 
the Biofield Energy Treated test formulation showed 
significant reduction of IL-1β secretion by 30.81%, 27.36%, 
23.92%, 18.40%, 11.27%, 21.16%, and 7.14% at 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053 
and 10.53 µg/mL, respectively as compared to the vehicle 
control. Both the Biofield Energy Treated and untreated test 
formulations demonstrated inhibition of IL-1β as compared 
to the LPS stimulated group. However, the Biofield Energy 
Treated test formulation exhibited better suppression than the 
untreated test formulation at 0.00001053, 0.0001053, and 
1.053 µg/mL by 48.63% (p≤0.001), 15.28%, and 6.28%, 
respectively as compared to the untreated test formulation. 
This indicates that the Biofield Energy Healing enhanced the 
herbomineral test formulation’s immunosuppressive property. 
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Figure 3. The effect of the test formulation on IL-1β secretion in LPS mediated splenocyte cells was measured after 48 hours of treatment. The values are 
represented as mean ± SEM. RAP: Rapamycin; LPS: Lipopolysaccharide; Con-A: Concanavalin-A. ***p≤0.001 vs. untreated test formulation. 
3.4. Estimation of MIP-1α Expression 
The effect of the Biofield Energy Treated test formulation 
on MIP-1α secretion is shown in Figure 4. The results show 
the Biofield Energy Treated test formulation significantly 
reduced the the MIP-1α expression by 5.25%, 22.33%, 
16.25%, 15.58%, and 21.83% at 0.00001053, 0.01053, 
0.1053, 1.053, and 10.53 µg/mL, respectively as compared to 
the vehicle control. The expression of MIP-1α was decreased 
by 25.57%, 24.81%, 1.43%, 10.45%, 11.34%, 10.79%, and 
7.31% at 0.00001053, 0.0001053, 0.001053, 0.01053, 
0.1053, 1.053 and 10.53 µg/mL, respectively in the untreated 
test formulation as compared to the vehicle control. The data 
indicates that there was a significant down-regulation of 
MIP-1α expression at 0.01053, 0.1053, 1.053 and 10.53 
µg/mL by 13.27%, 5.54%, 5.36%, and 15.67% (
*
p<0.05), 
respectively in the Biofield Energy Treated test formulation 
as compared to the untreated test formulation (as shown in 
Figure 4).  
 
Figure 4. Concentration-dependent effect of LPS mediated production of MIP-1α by the test formulation. For each concentration treatment, the level of MIP-
1α release was measured after 48 hours of treatment. The values are represented as mean ± SEM. *p<0.05 vs vehicle control. RAP: Rapamycin; LPS: 
Lipopolysaccharide; Con-A: Concanavalin-A. 
3.5. Estimation of IFN-γ Expression 
 
Figure 5. The effect of the test formulation on IFN-γ secretion in LPS mediated splenocyte cells was measured after 48 hours of treatment. The values are 
represented as mean ± SEM. RAP: Rapamycin; LPS: Lipopolysaccharide; Con-A: Concanavalin-A. 
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The estimation of IFN-γ expression in splenocyte cells 
after treatment with the Biofield Energy Treated and 
untreated test formulations is represented in Figure 5. The 
expression of IFN-γ was decreased by 47.06%, 45.72%, 
40.34%, 40.68%, 26.90%, 18.83%, and 31.10% at 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053 
and 10.53 µg/mL, respectively in the untreated test 
formulation as compared to the vehicle control. The Biofield 
Energy Treated test formulation showed significant inhibition 
of IFN-γ expression by 33.45%, 25.38%, 37.15%, 27.74%, 
32.44%, 23.03%, and 44.21% at 0.00001053, 0.0001053, 
0.001053, 0.01053, 0.1053, 1.053, and 10.53 µg/mL, 
respectively as compared to the vehicle control. The data 
indicated that there was a significant down-regulation of 
IFN-γ expression at 0.1053, 1.053, and 10.53 µg/mL by 
7.59%, 5.18%, and 19.02%, respectively in the Biofield 
Energy Treated test formulation as compared to the untreated 
test formulation group (demonstrated in Figure 5).  
4. Discussion 
The novel proprietary herbomineral formulation was 
designed, consisting of a combination of ashwagandha and 
the minerals zinc chloride, magnesium gluconate hydrate, 
and sodium selenate. Each of the individual components of 
this formulation has been proven to have immunomodulatory 
activities. Ashwagandha has been shown to inhibit TNF-α 
induced nuclear factor-kappa B (NF-κB) activation in human 
myelomonoblastic leukemia cells in a study conducted by 
Singh and Aggrawal (2007) [38]. Selenium is an essential 
trace element that plays an important role in protecting cells 
from oxidative stress. As a supplementation to the diet, 
selenium may reduce the risk of cardiomyopathy, cancer, and 
immune disorders in humans [39, 40]. Zinc deficiency 
influences the generation of cytokines, including IL-1β, IL-2, 
IL-6, and TNF-α. In response to zinc supplementation, 
plasma cytokines exhibit a dose-dependent response. The 
mechanism of action may reflect the ability of zinc to induce 
or inhibit the activation of NF-κB. The wide involvement of 
zinc in the immune system [41] includes an ability to 
influence the production and signaling of numerous 
inflammatory cytokines in a variety of cell types [42]. 
Magnesium sulfate reduced cytokine production in 
intrapartum women and term and preterm neonates, 
demonstrating effectiveness in those at risk for inflammation 
associated adverse perinatal outcomes, whereby magnesium 
plays a critical regulatory role in NF-κB activation, cytokine 
production, and disease pathogenesis [43]. TNF-α is a 
circulating factor and is also identified as a key regulator of 
the inflammatory response. Literature evidenced that it can 
interact with two different types of receptors, tumor necrosis 
factor receptor 1 and 2 (TNFR1 and TNFR2), which are 
differentially expressed in cells and tissues and initiate both 
distinct and overlapping signal transduction pathways. These 
diverse signaling cascades lead to a range of cellular 
responses, which include cell death, survival, differentiation, 
proliferation and migration [44]. In this experiment, the 
expression of TNF-α was further inhibited in the Biofield 
Energy Treated test formulation at five concentrations as 
compared to the vehicle control, and two concentrations as 
compared to the untreated test formulation group. Thus, it is 
assumed that the down-regulation of cellular response might 
be accelerated due to the Biofield Energy Healing 
administered to the Biofield Treated test formulation.  
The IL-1β is a pro-inflammatory cytokine that has been 
implicated in pain, inflammation, and autoimmune 
conditions. The level of IL-1β expression was significantly 
inhibited at two concentrations (0.00001053 and 0.0001053 
µg/mL) in the Biofield Energy Treated test formulation as 
compared to the untreated test formulation. It has been 
reported that the decreased production of IL-1β is helpful in 
the reduction of inflammation [45]. MIP-1α is a member of 
the chemokines, and has been shown to contribute to 
monocyte/macrophage and neutrophil chemotaxis and 
activation. The expression of MIP-1 alpha mRNA in 
macrophages is induced by a variety of stimuli [46]. It was 
also observed that the level of MIP-1α expression was 
significantly inhibited in the Biofield Energy Treated test 
formulation as compared to the untreated test formulation. 
This decreased production of MIP-1α in the Biofield Energy 
Treated test formulation might be due to the down-regulation 
of MIP-1α mRNA expression and protein synthesis via the 
generation of reactive oxygen species (ROS). Additionally, 
the decrease in MIP-1 alpha mRNA levels might be due to 
transcriptional inactivation and post-transcriptional 
destabilization [47]. IFN-γ is an extraordinarily pleotropic 
cytokine. It acts in both the innate and adaptive immune 
responses against pathogens and tumors, and also has the 
ability to maintain immune homeostasis [48]. The IFN-γ 
expression was significantly inhibited at 10.53 µg/mL in the 
Biofield Energy Treated test formulation as compared to the 
untreated test formulation. This decreased production of IFN-
γ in the Biofield Energy Treated test formulation might be 
due to the suppression of inflammatory molecules, alteration 
of apoptotic mediators, and the downregulation and nuclear 
translocation of STAT1 [49].  
Inflammation is the first response of the immune system to 
infection or irritation. It is caused by cytokines such as TNF-
α, IL-1, and IL-6 by eicosanoids such as prostaglandin E2 
(PGE2) [50]. Thus, inhibitors of these cytokines have been 
sought after as anti-inflammatory drugs. Biofield Therapies 
(such as Reiki, therapeutic touch, healing touch and other 
types of Energy Medicine) are complementary and 
alternative medicine modalities that are often utilized by a 
significant number of cancer patients. These therapies show 
strong evidence in reducing pain intensity in those suffering 
from chronic pain, and moderate evidence in reducing pain 
intensity in cancer populations [51, 52]. The Biofield Energy 
Treated test formulation strongly inhibited the pro-
inflammatory cytokines TNF-α, MIP-1α, IFN-γ, and IL-1β. 
Therefore, these results suggest that the Biofield Energy 
Treated test formulation may inhibit the inflammatory 
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response of splenocytes by modulating the signal 
transduction pathways.  
5. Conclusions 
Cell viability was assessed using MTT assay and the 
herbomineral formulation was found to be safe at all the 
tested concentrations. The level of TNF-α was significantly 
decreased by 8.35% at 10.53 µg/mL in the Biofield Energy 
Treated test formulation as compared to the untreated test 
formulation. Moreover, the level of IL-1β was significantly 
reduced by 48.63% (p≤0.001) and 15.28% at 0.00001053 
and 0.0001053 µg/mL, respectively in the Biofield Energy 
Treated test formulation as compared to the untreated test 
formulation. In addition, expression of MIP-1α was 
significantly reduced by 13.27% and 15.67% (p<0.05) at 
0.01053 and 10.53 µg/mL, respectively in the Biofield 
Energy Treated test formulation as compared to the 
untreated test formulation. Furthermore, the Biofield 
Energy Treated test formulation showed 19.02% down-
regulation of IFN-γ expression at 10.53 µg/mL as compared 
to the untreated test formulation.  
Overall, The Trivedi Effect
® 
- Biofield Energy Healing 
(TEBEH) administered remotely by the twenty Biofield 
Energy Healers to the test formulation significantly 
inhibited the activity of pro-inflammatory cytokines and 
showed immunosuppressive activity with a safe therapeutic 
index as compared with the untreated test formulation. 
Biofield Energy Healing shows great promise as a 
Complementary and Alternative Medicine (CAM) therapy 
and might play an important role in treating autoimmune 
diseases and inflammatory disorders like Lupus, Systemic 
Lupus Erythematosus, Hashimoto Thyroiditis, Type 1 
Diabetes, Asthma, Chronic peptic ulcers, Tuberculosis, 
Hepatitis, Chronic active hepatitis, Celiac Disease (gluten-
sensitive enteropathy), Addison Disease, Crohn's disease, 
Graves’ Disease, Pernicious and Aplastic Anemia, Sjogren 
Syndrome, Irritable Bowel Syndrome (IBS), Multiple 
Sclerosis, Rheumatoid arthritis, Chronic periodontitis, 
Ulcerative colitis, Chronic sinusitis, Myasthenia Gravis, 
Atherosclerosis, Vasculitis, Dermatitis, Diverticulitis, 
Rheumatoid Arthritis, Reactive Arthritis, Alopecia Areata, 
Psoriasis, Scleroderma, Fibromyalgia, Chronic Fatigue 
Syndrome, Vitiligo, Parkinson’s Disease, Alzheimer’s 
Disease, and stress etc. Biofield Energy Healing may also 
be useful in the prevention of immune-mediated tissue 
damage in cases of organ transplants (such as liver 
transplants, kidney transplants and heart transplants), as 
well as for anti-aging and improving overall health and 
quality of life. 
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